N-(1-aza-bicyclo[2,2,2]oct-3-yl)-2-methoxycinnamamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: N-(1-aza-bicyclo[2,2,2]oct-3-yl)-2-methoxycinnamamide
• 英文别名: (RS)-N-(1-azabicyclo[2.2.2]oct-3-yl)(E-3-(2-methoxyphenyl)propenamide)；(E)-N-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-methoxyphenyl)prop-2-enamide
• 化学式: C₁₇H₂₂N₂O₂
• 分子量: 286.374
• InChiKey: QODFPISBGYJKDV-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Novel piperidine derivative
  申请人：Ban Hitoshi

  公开号：US20050165057A1

  公开（公告）日：2005-07-28

  A compound of the formula (1): wherein m and n are independently an integer of 0 to 4, and m+n=4; L is cycloalkyl, substituted cycloalkyl, aromatic group, or substituted aromatic group; Y is aryl or substituted aryl; R is hydrogen, alkyl, etc.; R 31 , R 32 , R 33 , R 34 , R 35 and R 36 are the same or different and are selected, if two or more exist, independently from hydrogen, alkyl, etc., or a prodrug thereof, or a pharmaceutically acceptable salt of the same, which exhibits ACAT inhibitory activity, and is useful as an agent for treatment of hyperlipidemia and atherosclerosis.

  化合物的式子(1): 其中m和n独立地是0到4之间的整数，且m+n=4；L是环烷基，取代环烷基，芳香族基或取代芳香族基；Y是芳基或取代芳基；R是氢，烷基等；R31、R32、R33、R34、R35和R36相同或不同，如果存在两个或更多，则独立地从氢，烷基等中选择，或其前药，或其药学上可接受的盐，其表现出ACAT抑制活性，并且用作治疗高脂血症和动脉粥样硬化的药物。
• NOVEL PIPERIDINE DERIVATIVE
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：EP1500648A1

  公开（公告）日：2005-01-26

  A compound of the formula (1): wherein m and n are independently an integer of 0 to 4, and m+n=4; L is cycloalkyl, substituted cycloalkyl, aromatic group, or substituted aromatic group; Y is aryl or substituted aryl; R is hydrogen, alkyl, etc.; R31, R32, R33, R34, R35 and R36 are the same or different and are selected, if two or more exist, independently from hydrogen, alkyl, etc., or a prodrug thereof, or a pharmaceutically acceptable salt of the same, which exhibits ACAT inhibitory activity, and is useful as an agent for treatment of hyperlipidemia and atherosclerosis.

  式（1）的化合物： 其中 m 和 n 独立地为 0 至 4 的整数，且 m+n=4 ；L 为环烷基、取代环烷基、芳香基团或取代芳香基团；Y 为芳基或取代芳基；R 为氢、烷基等；R31、R32、R33、R34、R35 和 R36 相同或不同，且如果存在两个或多个，则独立地选自氢、烷基等、 或其原药，或其药学上可接受的盐，具有 ACAT 抑制活性，可作为治疗高脂血症和动脉粥样硬化的药物。
• NEW USE AND NOVEL N-AZABICYCLO-AMIDE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP1233964B1

  公开（公告）日：2005-06-22
• US6683090B1
  申请人：——

  公开号：US6683090B1

  公开（公告）日：2004-01-27